L40C-CRISPR.EFS.PAC
(Plasmid
#89393)
-
Purpose(Empty Backbone) Lentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA (hU6), PAC (Puromycin resistance) coexpression, EFS Promoter driven
-
Depositing Lab
-
Sequence Information
Ordering
This material is available to academics and nonprofits only.
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 89393 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 | |
Backbone
-
Vector backboneSIN40C
-
Modifications to backbonemodified pLKO5
-
Vector typeLentiviral, CRISPR
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Resource Information
-
Supplemental Documents
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
How to cite this plasmid
( Back to top)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
L40C-CRISPR.EFS.PAC was a gift from Dirk Heckl (Addgene plasmid # 89393 ; http://n2t.net/addgene:89393 ; RRID:Addgene_89393) -
For your References section:
CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Reimer J, Knoess S, Labuhn M, Charpentier EM, Gohring G, Schlegelberger B, Klusmann JH, Heckl D. Haematologica. 2017 Jun 1. pii: haematol.2017.164046. doi: 10.3324/haematol.2017.164046. 10.3324/haematol.2017.164046 PubMed 28572162
Map uploaded by the depositor.
